STAGE IV COLON CANCER AJCC V8
Clinical trials for STAGE IV COLON CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV COLON CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV COLON CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Tough-to-Treat colorectal cancer
Disease control OngoingThis study tests a combination of three drugs (cetuximab, LY3214996, and abemaciclib) in people with advanced colorectal cancer that has spread and no longer responds to standard therapy. The goal is to see if the combination can shrink tumors and improve survival. About 46 adult…
Matched conditions: STAGE IV COLON CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 17, 2026 03:11 UTC
-
New drug combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-stage study tests a combination of two drugs—trastuzumab deruxtecan (DS-8201a) and ceralasertib—in people with advanced solid tumors that have a HER2 mutation. The first part finds the safest dose and checks side effects. The second part compares the combo to DS-8201a …
Matched conditions: STAGE IV COLON CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
New combo therapy targets hard-to-treat colorectal cancer
Disease control OngoingThis study tests a new drug, SX-682, alone and with the immunotherapy nivolumab, in people with a specific type of advanced colorectal cancer that has spread or cannot be removed. The cancer must have a RAS mutation and be microsatellite stable (MSS), which often makes it harder …
Matched conditions: STAGE IV COLON CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New hope for tough colon cancer: drug cocktail targets resistant tumors
Disease control OngoingThis early-stage trial tests a combination of chemotherapy (FOLFOX), a blood-vessel blocker (bevacizumab), and two immunotherapy drugs (botensilimab and balstilimab) in 20 people with a type of colorectal cancer that has spread and is hard to treat (MSS metastatic). The goal is t…
Matched conditions: STAGE IV COLON CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
Immunotherapy combo shows promise for Hard-to-Treat colorectal cancer
Disease control OngoingThis study looks at whether adding an immunotherapy drug (nivolumab) to the usual two-drug treatment can better shrink tumors in people with a specific type of advanced colorectal cancer (BRAF-mutated, microsatellite stable). About 86 adults whose cancer has spread or can't be re…
Matched conditions: STAGE IV COLON CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
Home monitoring may keep cancer patients out of the ER
Symptom relief OngoingThis study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…
Matched conditions: STAGE IV COLON CANCER AJCC V8
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 17, 2026 03:13 UTC